See also: Generic Razadyne
Razadyne ER is a brand name of galantamine, approved by the FDA in the following formulation(s):
RAZADYNE ER (galantamine hydrobromide - capsule, extended release; oral)
Manufacturer: JANSSEN PHARMS
Approval date: April 1, 2005
Strength(s): EQ 16MG BASE [AB], EQ 24MG BASE [AB], EQ 8MG BASE [RLD][AB]
Has a generic version of Razadyne ER been approved?
A generic version of Razadyne ER has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Razadyne ER and have been approved by the FDA:
galantamine hydrobromide capsule, extended release; oral
Manufacturer: BARR
Approval date: September 15, 2008
Strength(s): EQ 16MG BASE [AB], EQ 24MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: IMPAX LABS
Approval date: May 27, 2009
Strength(s): EQ 16MG BASE [AB], EQ 24MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: MYLAN
Approval date: January 24, 2011
Strength(s): EQ 16MG BASE [AB], EQ 24MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: SUN PHARMA GLOBAL
Approval date: February 2, 2011
Strength(s): EQ 16MG BASE [AB], EQ 24MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: WATSON LABS
Approval date: December 15, 2008
Strength(s): EQ 16MG BASE [AB], EQ 24MG BASE [AB], EQ 8MG BASE [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Razadyne ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Controlled release galantamine composition
Patent 7,160,559
Issued: January 9, 2007
Inventor(s): McGee; John Paul & Gilis; Paul Marie Victor & De Weer; Marc Maurice Germain & de Condé; Valentin Florent Victor & de Bruijn; Herman Johannes Catherina & Van Dycke; Frederic Anne Rodolf
Assignee(s): Janssen Pharmaceutica N.V.
The present invention is concerned with controlled release compositions for oral administration comprising galantamine; and with processes of preparing such controlled release compositions.Patent expiration dates:
- December 20, 2019✓
- December 20, 2019
See also...
- Razadyne ER Extended-Release Capsules Consumer Information (Wolters Kluwer)
- Razadyne ER Consumer Information (Cerner Multum)
- Razadyne ER Advanced Consumer Information (Micromedex)
- Galantamine Consumer Information (Wolters Kluwer)
- Galantamine Extended-Release Capsules Consumer Information (Wolters Kluwer)
- Galantamine Solution Consumer Information (Wolters Kluwer)
- Galantamine Consumer Information (Cerner Multum)
- Galantamine Advanced Consumer Information (Micromedex)
- Galantamine Hydrobromide AHFS DI Monographs (ASHP)
No comments:
Post a Comment